Envestnet Asset Management Inc. Lowers Stock Holdings in Takeda Pharmaceutical Co. (NYSE:TAK)

Envestnet Asset Management Inc. lessened its holdings in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 9.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 891,183 shares of the company's stock after selling 93,495 shares during the quarter. Envestnet Asset Management Inc.'s holdings in Takeda Pharmaceutical were worth $13,252,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of New York Mellon Corp boosted its holdings in shares of Takeda Pharmaceutical by 17.2% in the fourth quarter. Bank of New York Mellon Corp now owns 104,892 shares of the company's stock valued at $1,389,000 after acquiring an additional 15,388 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Takeda Pharmaceutical by 35.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 253,551 shares of the company's stock worth $3,357,000 after purchasing an additional 66,386 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at approximately $1,447,000. HighTower Advisors LLC increased its holdings in shares of Takeda Pharmaceutical by 1.5% in the 4th quarter. HighTower Advisors LLC now owns 124,439 shares of the company's stock valued at $1,648,000 after acquiring an additional 1,852 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after purchasing an additional 1,976 shares during the period. Institutional investors and hedge funds own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK traded up $0.12 during midday trading on Tuesday, reaching $14.56. The company's stock had a trading volume of 3,241,793 shares, compared to its average volume of 2,031,109. Takeda Pharmaceutical Co. has a 12-month low of $12.80 and a 12-month high of $15.53. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.01 and a quick ratio of 0.52. The firm has a 50 day moving average price of $14.83 and a 200-day moving average price of $14.45. The stock has a market capitalization of $46.31 billion, a P/E ratio of 66.16 and a beta of 0.23.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The firm had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. As a group, equities analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.